Robert Brodsky, MD
Hematology · Baltimore, MDNPI 1194783712
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $16,475 of the $26,788 with a category attached, or 61.5%. AstraZeneca accounts for 90.0% of it on its own, with 1 other manufacturer making up the rest. 2025 is the largest year on record at $12,053, 6.0 times the $2,000 reported in 2020.
Across 21 payments — averaging $1275.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$24K
- Sobi, Inc$3K
Across 25 payments — averaging $17,408 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$429K
- National Marrow Donor Program$6K
What the payments were for
- Consulting fees$16,47562%
- Speaking & faculty fees$8,98534%
- Travel & lodging$1,0194%
- Food & beverage$1090%
- Education$2001%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 18 | $24,109 |
| Sobi, Inc | 3 | $2,679 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$26,788 in reported general payments places this provider in the 85th percentile of 28 hematology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cyclosporine | 14 | $7,144 |
| Cyclosporine ModifiedCyclosporine, Modified | 24 | $3,680 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 11 | $1,850 |
| ValacyclovirValacyclovir Hcl | 11 | $534 |
| Prednisone | 13 | $66 |
Paid to pharmacies, not to this prescriber.
Other hematology in Baltimore
- Jerry SpivakBaltimore$98K
- Michael KallenBaltimore$53K
- Gloria GerberBaltimore$41K
- Djordje AtanackovicBaltimore$11K
- Michael ColeBaltimore$7K
- Alison MoliternoBaltimore$3K
- Max BrodskyBaltimore$305
- Aaron RapoportBaltimore$296
- Jeffrey SeibelBaltimore$129
- Hector Mesa CorralesBaltimore$123
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.